Devyser Genomic Laboratories receives Accreditation from College of American Pathologists
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation...
In this case study, Dr. Papasavva describes her laboratory’s journey from traditional thalassemia testing to state-of-the-art NGS technology and what a difference this has made in their daily work.
Whitepaper
This whitepaper details how dd-cfDNA monitoring represents a significant advancement in the field of kidney transplantation. Offering a non-invasive and sensitive method for early detection of graft rejection can potentially improve patient outcomes and transform post-transplant care.
The study discussed in this whitepaper validates the feasibility of dd-cfDNA monitoring to differentiate between sources of dd-cfDNA (Pettersson et al., 2024). The study even highlighted the challenge faced by dd-cfDNA monitoring, as the assay detected dd-cfDNA from an organ explanted 8 years previously. The NGS-based methodology allows for scalable deployment of the technology, with the ability to analyze multiple samples with a turnaround time acceptable for clinical applications.
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation...
Read More
Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for...
Read More
Read More
Read More